Marc-Antoine Belaud-Rotureau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Marc-Antoine Belaud-Rotureau has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Nathalie Rioux-Leclercq
Université de Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en santé, environnement et travail) - UMR_S1085, 35000 Rennes, France; Service d'Anatomie et Cytologie Pathologiques, CHU de Rennes, 35000 Rennes, France
6 shared publications- Frédéric Dugay
Université Rennes, Inserm, EHESP (Ecole des Hautes Etudes en Santé Publique), IRSET (Institut de recherche en santé, environnement et travail), UMR 1085, 35000 Rennes, France
5 shared publications - Marion Beaumont
Service de Cytogénétique, CHU de Rennes, Rennes, France
4 shared publications - Sylvie Jaillard
Cytogenetics and Cell Biology Department, Rennes University Hospital, Rennes, France
4 shared publications - Karim Bensalah
Department of Urology, CHU Rennes, Rennes, France
3 shared publications Catherine Henry
2 shared publications
Latest Publications
- 1 October 2019
- Published by Elsevier in Human Pathology
- Vol. 92, 81-90
Diagnosis of uncommon renal epithelial neoplasms: performances of fluorescence in situ hybridization
- 1 October 2019
- Published by Elsevier in Human Pathology
- Vol. 92, 81-90
Diagnosis of uncommon renal epithelial neoplasms: performances of fluorescence in situ hybridization
- 1 December 2017
- Published by Elsevier in Morphologie
- Vol. 101 (335) , 261-262
Rôle du gène SOX3 dans le développement : à propos d’un fœtus 46,XX présentant une duplication Xq27.1
- 1 December 2017
- Published by Elsevier in Morphologie
- Vol. 101 (335) , 261-262
Rôle du gène SOX3 dans le développement : à propos d’un fœtus 46,XX présentant une duplication Xq27.1
- 1 December 2017
- Published by Elsevier in Morphologie
- Vol. 101 (335) , 241-242
Impact de l’hybridation in situ en fluorescence (FISH) pour le diagnostic des carcinomes rénaux : étude d’une série de 311 cas
- 1 December 2017
- Published by Elsevier in Morphologie
- Vol. 101 (335) , 241-242
Impact de l’hybridation in situ en fluorescence (FISH) pour le diagnostic des carcinomes rénaux : étude d’une série de 311 cas
- 1 December 2017
- Published by Elsevier in Morphologie
- Vol. 101 (335) , 256
Analyse chromosomique par puce à ADN (ACPA) en fœtopathologie et diagnostic prénatal : retour d’expérience du service de cytogénétique et biologie cellulaire du CHU de Rennes
- 1 December 2017
- Published by Elsevier in Morphologie
- Vol. 101 (335) , 256
Analyse chromosomique par puce à ADN (ACPA) en fœtopathologie et diagnostic prénatal : retour d’expérience du service de cytogénétique et biologie cellulaire du CHU de Rennes
- 1 September 2016
- Published by Elsevier in Morphologie
- Vol. 100 (330) , 180-181
Amplification d’ATM de type HSR dans un lymphome T de bas grade
- 1 September 2016
- Published by Elsevier in Morphologie
- Vol. 100 (330) , 180-181
Amplification d’ATM de type HSR dans un lymphome T de bas grade
- 1 September 2016
- Published by Elsevier in Morphologie
- Vol. 100 (330) , 171-172
Comparaison des performances des techniques de cytogénétique conventionnelle (caryotype) et moléculaire (FISH, ACPA) pour l’étude cytogénétique des leucémies lymphoïdes chroniques au diagnostic
- 1 September 2016
- Published by Elsevier in Morphologie
- Vol. 100 (330) , 171-172
Comparaison des performances des techniques de cytogénétique conventionnelle (caryotype) et moléculaire (FISH, ACPA) pour l’étude cytogénétique des leucémies lymphoïdes chroniques au diagnostic
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e16079
Correlation of MET complete status and outcome in patients with metastatic clear cell renal cell carcinoma (m-ccRCC) treated by sunitinib.
E16079 Background: Clear cell renal cell carcinoma (ccRCC) are highly metastatic tumors. Anti-vascular growth epithelial factor (VEGF) therapies are currently used in first line of metastatic ccRCC but most patients develop resistance to these treatments. Cabozantinib, an inhibitor of tyrosine kinases including VEGFR, MET and AXL recently shows interesting results in second line treatment. Moreover, the HGF/MET signaling pathway implicated in angiogenesis may be responsible for resistance to anti-VEGF therapy. To better understand MET role in metastatic ccRCC and potential resistance, we assessed MET complete status in a well-characterized population of 90 patients with metastatic ccRCC treated by first line sunitinib therapy. Methods: For this purpose, we studied MET expression by immunohistochemistry (IHC), MET amplification by fluorescence in situ hybridization (FISH) on formalin-fixed paraffin-embeded (FFPE) samples and MET mutation by next generation sequencing (NGS) on frozen samples in their 90 primary tumors. MET status was then correlated to pathological criteria using Chi-squared test and clinical outcome using Kaplan Meier curves compared by log rank test. Results: 31.1% of ccRCCs had low expression of MET (absent to weak intensity by IHC) versus 68.9% with high expression (moderate to strong intensity). High expression of MET was associated with gain in FISH analyses (p = 0.0284) without amplification. No mutation was detected by NGS. High expression of MET was associated with lymph node invasion and sarcomatoid component (p = 0.004 and p = 0.029). No statistical differences were observed between the two groups of patients in terms of progression free survival and overall survival after sunitinib introduction (p = 0.72 and p = 0.93). Conclusions: This study is the first to analyze complete MET status in metastatic ccRCC treated by sunitinib. High expression of MET, although not associated with sunitinib resistance, may suggest a benefit from MET inhibitors.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e16079
Correlation of MET complete status and outcome in patients with metastatic clear cell renal cell carcinoma (m-ccRCC) treated by sunitinib.
E16079 Background: Clear cell renal cell carcinoma (ccRCC) are highly metastatic tumors. Anti-vascular growth epithelial factor (VEGF) therapies are currently used in first line of metastatic ccRCC but most patients develop resistance to these treatments. Cabozantinib, an inhibitor of tyrosine kinases including VEGFR, MET and AXL recently shows interesting results in second line treatment. Moreover, the HGF/MET signaling pathway implicated in angiogenesis may be responsible for resistance to anti-VEGF therapy. To better understand MET role in metastatic ccRCC and potential resistance, we assessed MET complete status in a well-characterized population of 90 patients with metastatic ccRCC treated by first line sunitinib therapy. Methods: For this purpose, we studied MET expression by immunohistochemistry (IHC), MET amplification by fluorescence in situ hybridization (FISH) on formalin-fixed paraffin-embeded (FFPE) samples and MET mutation by next generation sequencing (NGS) on frozen samples in their 90 primary tumors. MET status was then correlated to pathological criteria using Chi-squared test and clinical outcome using Kaplan Meier curves compared by log rank test. Results: 31.1% of ccRCCs had low expression of MET (absent to weak intensity by IHC) versus 68.9% with high expression (moderate to strong intensity). High expression of MET was associated with gain in FISH analyses (p = 0.0284) without amplification. No mutation was detected by NGS. High expression of MET was associated with lymph node invasion and sarcomatoid component (p = 0.004 and p = 0.029). No statistical differences were observed between the two groups of patients in terms of progression free survival and overall survival after sunitinib introduction (p = 0.72 and p = 0.93). Conclusions: This study is the first to analyze complete MET status in metastatic ccRCC treated by sunitinib. High expression of MET, although not associated with sunitinib resistance, may suggest a benefit from MET inhibitors.
- 1 August 2014
- Published by Elsevier in Human Pathology
- Vol. 45 (8) , 1639-1646
Cytoplasmic PAR-3 protein expression is associated with adverse prognostic factors in clear cell renal cell carcinoma and independently impacts survival
- 1 August 2014
- Published by Elsevier in Human Pathology
- Vol. 45 (8) , 1639-1646
Cytoplasmic PAR-3 protein expression is associated with adverse prognostic factors in clear cell renal cell carcinoma and independently impacts survival
- 1 March 2014
- Published by Elsevier in Morphologie
- Vol. 98 (320) , 1-7
Cytogénétique des carcinomes rénaux
- 1 March 2014
- Published by Elsevier in Morphologie
- Vol. 98 (320) , 1-7
Cytogénétique des carcinomes rénaux